脂必泰联合阿托伐他汀治疗冠状动脉粥样硬化性心脏病合并高脂血症的疗效及对超敏C-反应蛋白水平的影响

Therapeutic effect of Zhibitai combined with atorvastatin in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of hypersensitive C-reactive protein

目的 研究阿托伐他汀联合脂必泰治疗冠状动脉粥样硬化性心脏病(冠心病)合并高脂血症的疗效及其对超敏C-反应蛋白( hsCRP)水平的影响.方法 随机抽取景德镇第三人民医院2016 年9 月至2018年9月收治的冠心病合并高脂血症患者136例,采用随机综合平衡法分为对照组和联合组各68例.对照组采用阿托伐他汀治疗,联合组采用脂必泰联合阿托伐他汀治疗.观察患者治疗效果,包括血脂达标率及治疗过程中不良反应发生情况,同时对患者治疗前及治疗后甘油三酯(TG)、12 h血清总胆固醇( TC)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)及hsCRP等指标进行测定.结果 (1)联合组血脂达标率(89.86%)高于对照组血脂达标率(59.70%),差异有统计学意义(χ^2 =14.915,P=0.000). (2)联合组不良反应发生率(1.45%)低于对照组不良反应发生率(17.91%),差异有统计学意义( χ^2 =8.836,P=0.003). (3)测定结果显示,联合组TC、TG、LDL-C、hsCRP等指标均低于对照组及治疗前,而HDL-C指标高于对照组及治疗前,差异均有统计学意义(t=20.800、4.903、11.657、4.346、6.262、P=0.000、0.000、0.000、0.000、0.000).结论 脂必泰联合阿托伐他汀对冠心病合并高脂血症患者具有显著效果,可有效控制其TC、TG、LDL-C、HDL-C及hsCRP等指标,提高血脂控制率,且安全性较高.

Objective To study the effect of atorvastatin combined with Zhibitai in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of high-sensitivity C-reactive protein ( hsCRP). Methods A total of 136 patients with coronary heart disease and hyperlipidemia admitted to the Third People 's Hospital of Jingdezhen from September 2016 to September 1818 were randomly divided into control group and combi-nation group using stochastic comprehensive balance method , with 68 cases in each group.The control group was treated with atorvastatin and the combination group was treated with lipidine plus atorvastatin .The patient's treatment effect,including the blood lipid compliance rate and the occurrence of adverse reactions during the treatment were observed,as well as the patient's pre-and post-treatment triglyceride ( TG),12h serum total cholesterol ( TC), high-density lipoprotein-cholesterol ( HDL-C), low density lipoprotein-cholesterol ( LDL-C) and high-sensitivity C-reactive protein(hsCRP)and other indicators were measured.Results (1)The blood lipid compliance rate(89.86%) in the combined group was higher than that in the control group (59.70%),the difference was statis-tically significant(χ^2 =14.915,P=0.000).(2)The incidence of adverse reactions in the combined group (1.45%) was lower than that in the control group (17.91%), the difference was statistically significant ( χ^2 =8.836, P = 0.003).(3)The results showed that the TC,TG,LDL-C,hsCRP and other indicators of the combined group were lower than those of the control group and before treatment ,while the HDL-C index of the combined groupwas higher than that of the control group and before treatment ,the differences were statistically significant ( t=20.800,4.903, 11.657,4.346,6.262,P=0.000,0.000,0.000,0.000,0.000).Conclusion Zhibitai combined with atorvastatin in the treatment of coronary heart disease patients with hyperlipidemia has remarkable effect .It can accurately control TC,TG,LDL-C,HDL-C and hsCRP,improve blood lipid control rate.